Using receiver operating characteristic curve analysis, AUCs were 0.70, 0.76, 0.75, and 0.78 for decline at week 4, 8, 12,

and 24, respectively, for predicting response at week 78. We also investigated the discriminatory values of absolute HBsAg levels (in log IU/mL) and HBV DNA decline, but these proved inferior to HBsAg declines. Next, we proceeded to investigate the optimal cutoff point, according to our preset criteria, in HBsAg decline at week 4, 8, 12, and 24 for prediction of response. A cutoff of any decline in serum HBsAg level from baseline (i.e., the HBsAg level on-treatment was lower than the level measured at baseline: log(HBsAgon-treatment) − log(HBsAgbaseline) < 0) proved superior. Subsequently, R428 prediction of response at weeks 12 and 24 was superior to weeks 4 and 8, because it allowed for more patients to be stopped, while maintaining >90% of responders on-treatment (Fig. 3). In addition, learn more week 12 was superior to week 24 because it allowed for earlier discontinuation of therapy, while maintaining high predictive values for both response and HBsAg loss (Table 2). At week 12, 69% of patients achieved a decline in HBsAg when compared to baseline. Of the 31% who did not, only 3% achieved a response at week 78. Consequently,

the NPV of the presence of any decline in HBsAg at week 12 is 97% for prediction of response at week 78. Comparable NPVs were found for prediction of response at week 24 (Table 2, Fig. 4). Of those patients who developed a decline at week 12, 25% achieved a response at week 78, check details and 12% achieved HBsAg loss. Of the 149 patients with LTFU data available, 36 (24%) had a response at LTFU. Similar decline patterns were observed for responders and nonresponders at LTFU when compared to (non)responders at week 78; responders showed a steeper on-treatment decline. Declines were 0.53 log IU/mL versus 2.76 log IU/mL at week

52, for (non)responders, respectively (P = 0.007 for weeks 4 and 8, P ≤ 0.002 for all other time points), and the difference was sustained after treatment. Furthermore, of the patients who did not achieve a decline through 12 weeks of therapy, only 5% achieved a sustained response through LTFU and none lost HBsAg (Table 3). We report the first large study on serum HBsAg decline during PEG-IFN treatment for HBeAg-positive CHB in relation to a sustained off-treatment response. One year of therapy with PEG-IFN significantly reduced serum HBsAg levels, and the decrease was sustained through post-treatment follow-up. HBsAg decline was significantly more pronounced in patients who achieved a response (HBeAg loss and HBV DNA < 10,000 copies/mL). Furthermore, we found that reliable prediction of nonresponse to PEG-IFN is possible as early as week 12 of therapy, based on the absence of a decline in serum HBsAg.